Literature DB >> 20521963

Cervical motion preservation using mesenchymal progenitor cells and pentosan polysulfate, a novel chondrogenic agent: preliminary study in an ovine model.

Tony Goldschlager1, Peter Ghosh, Andrew Zannettino, Stan Gronthos, Jeffrey V Rosenfeld, Silviu Itescu, Graham Jenkin.   

Abstract

OBJECT: There is an unmet need for a procedure that could generate a biological disc substitute while at the same time preserving the normal surgical practice of achieving anterior cervical decompression. The objective of the present study was to test the hypothesis that adult allogeneic mesenchymal progenitor cells (MPCs) formulated with a chondrogenic agent could synthesize a cartilaginous matrix when implanted into a biodegradable carrier and cage, and over time, might serve as a dynamic interbody spacer following anterior cervical discectomy (ACD).
METHODS: Eighteen ewes were divided randomly into 3 groups of 6 animals. Each animal was subjected to C3-4 and C4-5 ACD followed by implantation of bioresorbable interbody cages and graft containment plates. The cage was packed with 1 of 3 implants. In Group A, the implant was Gelfoam sponge only. In Group B, the implant consisted of Gelfoam sponge with 1 million MPCs only. In Group C, the implant was Gelfoam sponge with 1 million MPCs formulated with the chondrogenic agent pentosan polysulfate (PPS). In each animal the cartilaginous endplates were retained intact at 1 level, and perforated in a standardized manner at the other level. Allogeneic ovine MPCs were derived from a single batch of immunoselected and culture-expanded MPCs isolated from bone marrow of outbred sheep (mixed stock). Radiological and histological measures were used to assess cartilage formation and the presence or absence of new bone formation.
RESULTS: The MPCs with or without PPS were safe and well-tolerated in the ovine cervical spine. There was no significant difference between groups in the radiographic or histological outcome measures, regardless of whether endplates were perforated or retained intact. According to CT scans obtained at 3 months after the operation, new bone formation within the interbody space was observed in the Gelfoam only group (Group A) in 9 (75%) of 12 interbody spaces, and 11 (92%) of 12 animals in the MPC cohort (Group B) had new bone formation within the interbody space. Significantly, in the MPC & PPS group (Group C), there were only 1 (8%) of 12 levels with new bone formation (p = 0.0009 vs Group A; p = 0.0001 vs Group B). According to histological results, there was significantly more cartilaginous tissue within the interbody cages of Group C (MPC & PPS) compared with both the control group (Group A; p = 0.003) and the MPC Group (p = 0.017).
CONCLUSIONS: This study demonstrated the feasibility of using MPCs in combination with PPS to produce cartilaginous tissue to replace the intervertebral disc following ACD. This biological approach may offer a means preserving spinal motion and offers an alternative to fusion to artificial prostheses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20521963     DOI: 10.3171/2010.3.FOCUS1050

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  9 in total

Review 1.  The role of stem cell therapies in degenerative lumbar spine disease: a review.

Authors:  David Oehme; Tony Goldschlager; Jeffrey V Rosenfeld; Peter Ghosh; Graham Jenkin
Journal:  Neurosurg Rev       Date:  2015-03-07       Impact factor: 3.042

Review 2.  Animal models of spinal injury for studying back pain and SCI.

Authors:  Shakti A Goel; Vicky Varghese; Tyfik Demir
Journal:  J Clin Orthop Trauma       Date:  2020-07-08

Review 3.  Cell sources for nucleus pulposus regeneration.

Authors:  Nevenka Kregar Velikonja; Jill Urban; Mirjam Fröhlich; Cornelia Neidlinger-Wilke; Dimitris Kletsas; Urska Potocar; Sarah Turner; Sally Roberts
Journal:  Eur Spine J       Date:  2013-12-03       Impact factor: 3.134

Review 4.  Biological Treatment Approaches for Degenerative Disk Disease: A Literature Review of In Vivo Animal and Clinical Data.

Authors:  Yu Moriguchi; Marjan Alimi; Thamina Khair; George Manolarakis; Connor Berlin; Lawrence J Bonassar; Roger Härtl
Journal:  Global Spine J       Date:  2016-01-27

5.  Regenerative and immunogenic characteristics of cultured nucleus pulposus cells from human cervical intervertebral discs.

Authors:  Stefan Stich; Meaghan Stolk; Pierre Pascal Girod; Claudius Thomé; Michael Sittinger; Jochen Ringe; Martina Seifert; Aldemar Andres Hegewald
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

6.  Pentosan polysulfate binds to STRO-1+ mesenchymal progenitor cells, is internalized, and modifies gene expression: a novel approach of pre-programing stem cells for therapeutic application requiring their chondrogenesis.

Authors:  Jiehua Wu; Susan Shimmon; Sharon Paton; Christopher Daly; Tony Goldschlager; Stan Gronthos; Andrew C W Zannettino; Peter Ghosh
Journal:  Stem Cell Res Ther       Date:  2017-12-13       Impact factor: 6.832

7.  A Comparison of Two Ovine Lumbar Intervertebral Disc Injury Models for the Evaluation and Development of Novel Regenerative Therapies.

Authors:  Chris D Daly; Peter Ghosh; Tanya Badal; Ronald Shimmon; Graham Jenkin; David Oehme; Justin Cooper-White; Idrees Sher; Ronil V Chandra; Tony Goldschlager
Journal:  Global Spine J       Date:  2018-06-10

Review 8.  A Review of Animal Models of Intervertebral Disc Degeneration: Pathophysiology, Regeneration, and Translation to the Clinic.

Authors:  Chris Daly; Peter Ghosh; Graham Jenkin; David Oehme; Tony Goldschlager
Journal:  Biomed Res Int       Date:  2016-05-22       Impact factor: 3.411

9.  Total disc replacement using tissue-engineered intervertebral discs in the canine cervical spine.

Authors:  Yu Moriguchi; Jorge Mojica-Santiago; Peter Grunert; Brenton Pennicooke; Connor Berlin; Thamina Khair; Rodrigo Navarro-Ramirez; Rodolfo J Ricart Arbona; Joseph Nguyen; Roger Härtl; Lawrence J Bonassar
Journal:  PLoS One       Date:  2017-10-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.